Turenne Santé and Sodero have acquired a majority stake in Vedalab, a leading rapid in vitro diagnostic test manufacturer, to support its international expansion and product development.

Target Information

Vedalab, established in 1991 by Raphaël Donati, is a prominent leader in the design and manufacturing of rapid in vitro diagnostic tests. The company offers over 300 products that are distributed across more than 130 countries, making it a global reference in its field. Known for its high-quality testing solutions, Vedalab has earned significant recognition in the healthcare sector.

With its strong position in the rapidly growing market for diagnostic tests, Vedalab has been proactive in adapting to new regulatory requirements and expanding its product range. The company’s quality management system is already certified under the In Vitro Diagnostic Regulation (IVDR), ensuring its products meet stringent safety and reliability standards.

Industry Overview in France

The in vitro diagnostics market in France is characterized by robust growth driven by increased demand for early disease detection and the need for rapid testing solutions, particularly in light of the COVID-19 pandemic. The French government and regulatory bodies ar